PA8849601A1 - Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos - Google Patents

Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos

Info

Publication number
PA8849601A1
PA8849601A1 PA20098849601A PA8849601A PA8849601A1 PA 8849601 A1 PA8849601 A1 PA 8849601A1 PA 20098849601 A PA20098849601 A PA 20098849601A PA 8849601 A PA8849601 A PA 8849601A PA 8849601 A1 PA8849601 A1 PA 8849601A1
Authority
PA
Panama
Prior art keywords
monoclonal antibodies
ferroportina
same
count
reticulocite
Prior art date
Application number
PA20098849601A
Other languages
English (en)
Spanish (es)
Inventor
Doen Mun Leung Donmienne
Luan Peng
Vincent Manetta Joseph
Tang Ying
Ryan Witcher Derrick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PA8849601A1 publication Critical patent/PA8849601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20098849601A 2008-12-05 2009-11-23 Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos PA8849601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US23981809P 2009-09-04 2009-09-04

Publications (1)

Publication Number Publication Date
PA8849601A1 true PA8849601A1 (es) 2010-07-27

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098849601A PA8849601A1 (es) 2008-12-05 2009-11-23 Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos

Country Status (25)

Country Link
EP (1) EP2373335B1 (https=)
JP (1) JP5713917B2 (https=)
KR (1) KR101353117B1 (https=)
CN (1) CN102238962B (https=)
AR (1) AR074398A1 (https=)
AU (1) AU2009322587B2 (https=)
BR (1) BRPI0922288A2 (https=)
CA (1) CA2745618C (https=)
CY (1) CY1117355T1 (https=)
DK (1) DK2373335T3 (https=)
EA (1) EA020472B1 (https=)
ES (1) ES2566343T3 (https=)
HR (1) HRP20160302T1 (https=)
HU (1) HUE028585T2 (https=)
IL (1) IL212731A0 (https=)
MX (1) MX2011005939A (https=)
NZ (1) NZ592545A (https=)
PA (1) PA8849601A1 (https=)
PL (1) PL2373335T3 (https=)
SG (1) SG171960A1 (https=)
SI (1) SI2373335T1 (https=)
TW (1) TW201023891A (https=)
UA (1) UA104741C2 (https=)
WO (1) WO2010065496A1 (https=)
ZA (1) ZA201103941B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871116A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
ES2500066T3 (es) * 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso

Also Published As

Publication number Publication date
CA2745618C (en) 2014-06-10
AR074398A1 (es) 2011-01-12
SI2373335T1 (sl) 2016-04-29
UA104741C2 (uk) 2014-03-11
ZA201103941B (en) 2012-11-28
CN102238962B (zh) 2014-02-12
EP2373335A1 (en) 2011-10-12
KR101353117B1 (ko) 2014-02-17
JP5713917B2 (ja) 2015-05-07
BRPI0922288A2 (pt) 2018-08-28
SG171960A1 (en) 2011-07-28
DK2373335T3 (en) 2016-05-02
TW201023891A (en) 2010-07-01
CN102238962A (zh) 2011-11-09
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
HUE028585T2 (en) 2016-12-28
CA2745618A1 (en) 2010-06-10
HRP20160302T1 (hr) 2016-04-22
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
JP2012510814A (ja) 2012-05-17
KR20110084996A (ko) 2011-07-26
MX2011005939A (es) 2011-06-27
ES2566343T3 (es) 2016-04-12
HK1158977A1 (zh) 2012-07-27
WO2010065496A1 (en) 2010-06-10
IL212731A0 (en) 2011-07-31
AU2009322587B2 (en) 2013-09-26
CY1117355T1 (el) 2017-04-26
PL2373335T3 (pl) 2016-08-31
EP2373335B1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
PA8849601A1 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
DOP2020000032A (es) Proteínas de unión específicas y sus usos
UY33144A (es) Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana
UA109633C2 (uk) Антитіло людини проти тканинного фактора
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
PA8849001A1 (es) Anticuerpos de c-met
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
MX2019002967A (es) Anticuerpos de union a cd3.
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
MX2019005251A (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
EP2170075A4 (en) MARKED INHIBITORS OF PROSTATE SPECIFIC MEMBRANEANT (PSMA), BIOLOGICAL ASSESSMENT AND USE AS IMAGING AGENT
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
CO6531481A2 (es) Proteinas de enlace al antigeno il-23 humanas
EA201070518A1 (ru) Композиция по уходу за волосами
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
UA105760C2 (uk) Антитіло проти bst2
CL2008003190A1 (es) Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
UY32915A (es) Proteínas de únión específicas y sus usos
MX2022008266A (es) Metodos para el almacenamiento de sangre completa y composiciones de esta.